POTENTIAL FRAUD ISSUES IN THE OPERATION OF PHARMACY BENEFIT MANAGEMENT ENTITIES

Similar documents
PBM REGULATION,INVESTIGATION,PROSE CUTION,AND COMPLIANCE PHARMA AUDIOCONFERENCE FEBRUARY 10, 2004

Federal and State Litigation Regarding Pharmacy Benefit Managers

DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All NEW YORK WORKFORCE MEMBERS

HEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036

DEVELOPMENTS IN THE PRESCRIPTION DRUG MARKET: OVERSIGHT. Before the Full House Committee on Oversight and Government Reform.

Compliance and Fraud, Waste, and Abuse Awareness Training. First Tier, Downstream, and Related Entities

Medicare Parts C & D Fraud, Waste, and Abuse Training and General Compliance Training. Developed by the Centers for Medicare & Medicaid Services

GERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036

DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All MASSACHUSETTS WORKFORCE MEMBERS

Medicare Parts C & D Fraud, Waste, and Abuse Training and General Compliance Training

CHAPTER 58-29E PHARMACY BENEFITS MANAGEMENT

PREVENTION, DETECTION, AND CORRECTION OF FRAUD, WASTE AND ABUSE

Medicare Parts C & D Fraud, Waste, and Abuse Training

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII

COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS. Judd Katz JD MHA November 2016

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016

REGULATORY ISSUES IMPACTING SUPPLY CHAIN

Developed by the Centers for Medicare & Medicaid Services Issued: February, 2013

The Intersection of Specialty Pharmacy and the Law

ALABAMA MEDICAID AGENCY ADMINISTRATIVE CODE CHAPTER 560-X-4 PROGRAM INTEGRITY DIVISION TABLE OF CONTENTS

Developed by the Centers for Medicare & Medicaid Services

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION ) lasetco cv

The People of the State of New York, by their attorney, Eliot Spitzer, Attorney General of

Supplemental Special Advisory Bulletin: Independent Charity. Patients who cannot afford their cost-sharing obligations

Senate Amendment to Senate Bill No. 539 (BDR ) Title: Yes Preamble: No Joint Sponsorship: No Digest: Yes

This course is designed to provide Part B providers with an overview of the Medicare Fraud and Abuse program including:

MATTHEW T. SCHELP. St. Louis, MO office:

Industry Funding of Continuing Medical Education

Pharmacy Benefit Manager Licensure and Solvency Protection Act

Certifying Employee Training Navicent Health s Corporate Integrity Agreement Year Two

Corporate Compliance Program. Intended Audience: All SEH Associates 2016 Content Expert: Lisa Frey -

Analysis of the New Medicare Part D Drug Benefit and Changes to Medicare Part B Reimbursement: New Rules of the Road

DEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of Inspector General s Use of Agreements to Protect the Integrity of Federal Health Care Programs

DAVID A. BALTO ATTORNEY AT LAW 1325 G STREET, NW SUITE 500 WASHINGTON, DC 20005

MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE. Reporting Requirements: Audit Preparedness for PDPs and Manufacturers

National Policy Library Document

Improving Integrity in Nursing Centers

Legal Issues Pertaining to Athletic Trainers

Lifetime Limits Effective September 23, 2010, payors are prohibited from placing lifetime dollar limits on medical claims.

Track III-A. Creating Relationships with Prescription Drug Plans and Managed Care Organizations

Objectives: Pharmacist Liability

STATEMENT OF MICHAEL F. HERTZ DEPUTY ASSISTANT ATTORNEY GENERAL CIVIL DIVISION UNITED STATES DEPARTMENT OF JUSTICE BEFORE THE

LIFEBLOOD OF THE SUCCESSFUL PHARMACY: MARKETING, JOINT VENTURES, AND ARRANGEMENTS WITH REFERRAL SOURCES WHILE REMAINING WITHIN LEGAL PARAMETERS

ANTI-FRAUD PLAN INTRODUCTION

Amy Bingham, Compliance Director Reviewed Only Date: 6/05,1/31/2011, 1/24/2012 Supersedes and replaces: "CC-02 - Anti-

Fraud and Abuse Compliance for the Health IT Industry

Region 10 PIHP FY Corporate Compliance Program Plan

Health Care Fraud Challenges to Medicare, Medicaid and Commercial Plans October 5, 2018

Subject: Pharmacy Services & Formulary Management (Page 1 of 5)

The Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective

STATE OF NEW JERSEY. SENATE, No th LEGISLATURE. Sponsored by: Senator NIA H. GILL District 34 (Essex and Passaic)

GETTING SERIOUS ABOUT MEDICAID COMPLIANCE:SECTION 6402 OF PPACA AND THE DUTY OF DISCLOSURE OF IDENTIFIED OVERPAYMENTS 7/14/10

NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work

PBM MODEL A A MODEL ACT RELATING TO PHARMACY BENEFIT MANAGERS*

Health Care Fraud for Physicians

The Orange County District Attorney charges that in Orange County, California, the law was violated as follows:

CBI Pharmaceutical Compliance Congress Washington, D.C.

Web Seminar. Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care.

Anti-Kickback Statute and False Claims Act Enforcement

Compliance Program. Health First Health Plans Medicare Parts C & D Training

Vendor Code of Business Conduct & Ethics

Potential Perils of Using New Media in Marketing and Promotion. Christina M. Markus (202)

FEDERAL DEFICIT REDUCTION ACT POLICY

Commitment to Compliance

NO. 80. AN ACT RELATING TO INCREASING TRANSPARENCY OF PRESCRIPTION DRUG PRICING AND INFORMATION. (S.115)

Coding Partners in Patient Safety

Pharmacy Compliance- Credentialing, HIPAA and Fraud, Waste and Abuse (FWA) ACPE# L04-P ACPE# L04-T

FRAUD, WASTE, & ABUSE (FWA) for Brokers. revised 10/17

ANCILLARY services: How to Stay Out of Trouble. The neurosurgical minefield Informed consent

v. INDICTMENT NO. "-;fklt',j ~-- lfr/t

The False Claims Act and Off-Label Promotion: Understanding and Minimizing the Risks for Pharmaceutical Manufacturers

OFFICE OF INSPECTOR GENERAL WORK PLAN FISCAL YEAR 2006 MEDICARE HOSPITALS

CONSENT JUDGMENT. and Unfair Trade Practices Act, Chapter 501, Part II, Florida Statutes (2003), having filed a

The Management of Specialty Drugs: Opportunities and Challenges

Private Investment Fund Liability Insurance Management and Professional Liability Coverage Part

I. PURPOSE. A. The primary objectives of Molina Healthcare s Transition Policy and Procedure are:

Bogies: Federal Anti- Kickback Law & EMS Contracting - Emerging Issues Pamela L. Johnston Foley & Lardner LLP Partner, Los Angeles.

From the Office Suite to Cell Block C: Potential Criminal and Regulatory Implications of Pharma/Biotech/Device Products Liability Lawsuits

1 SB By Senators Beasley, Smitherman, Irons, Bussman and Ross. 4 RFD: Health. 5 First Read: 12-APR-11. Page 0

Industry Consolidation: Role of Compliance in Mergers, Acquisitions, and Divestitures

LITIGATING AWP. Mitch Lazris/Lyndon Tretter Hogan & Hartson L.L.P. November 15, 2002

False Claims Liability, Anti-Retaliation Protections, and Detecting and Responding to Fraud, Waste, and Abuse

Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis

PLEASE CHECK ALL BOXES THAT APPLY AND COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM

False Claims Prevention

The Orange County District Attorney charges that in Orange County, California, the law was violated as follows:

Inside: Critical information about your company s prescription drug benefit.

Building a Strategic Plan for Physician Employment and Practice Acquisition

COMPLIANCE; It s Not an Option

Ridgecrest Regional Hospital Compliance Manual

AGENCY POLICY. IDENTIFICATION NUMBER: CCD001 DATE APPROVED: Nov 1, 2017 POLICY NAME: False Claims & Whistleblower SUPERSEDES: May 18, 2009

FAST BREAK : HOLIDAY GIFTS Jake Harper December 18, Morgan, Lewis & Bockius LLP

VENDOR PROGRAM. Vendors must complete the Vendor Screening and Disclosure Form as follows: *must be completed prior to any signed purchase order

Charging, Coding and Billing Compliance

Kroll Ontrack, LLC Prescription Drug Plan. Plan Document and Summary Plan Description

Medicare Part D: Retiree Drug Subsidy

Blue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - Pharmacy

EFFECTIVE DATE August 17, ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors

88 Section 6 Get Information about Prescription Drug Coverage

Transcription:

POTENTIAL FRAUD ISSUES IN THE OPERATION OF PHARMACY BENEFIT MANAGEMENT ENTITIES James G. Sheehan Associate United States Attorney 615 Chestnut Street, Suite 1250 Philadelphia, PA 19106 Phone: (215) 861-8301 E-mail: Jim.Sheehan@usdoj.gov

DISCLAIMER My own opinions, not the official position of Department of Justice General material in my presentation is not directed at any single company. Where reference is made to a particular company, it is based on public record or a published report. Every defendant in a publicly filed action has the right to a trial on any allegations in the Government complaint. Most consent orders and settlements do not contain any admission of the allegations by the defendant.

PBM ISSUES Transparency Trust(breach of trust=mail fraud) Recommend drugs and switches of drugs(kickback issue) Cost management(fiduciary, intent to create false impression) Professional Responsibility and Accountability(loyal and faithful service,fiduciary responsibility)

PBM ISSUES FOR MANUFACTURERS Conspiracy Aiding and Abetting cause to be submitted false claims Kickbacks-Medicare,Public Contracts,Commercial Bribery Best Price Inducing breach of duty

FLAWED PREMISE OF SWITCHING PROGRAMS DIFFERENT CHEMICAL COMPOUNDS IN A THERAPEUTIC CATEGORY ARE THERAPEUTIC EQUIVALENTS INCONSISTENT WITH MANUFACTURER S MESSAGE INCONSISTENT WITH CONSUMER EXPECTATIONS AND EXPERIENCE

PHARMACY BENEFIT MANAGEMENT ENTITIES Not just freestanding PBMs Health plans PBM subsidiaries of health plans Pharmacy providers/consultants to skilled nursing facilities, hospitals,other residential facilities Pharmacy providers to dialysis centers Practice management firms with significant drug/device component

FRAUD RISKS(1) Kickbacks to induce Medicare referrals or to cause PBM to act against the interest of patient or client. Interference with trust relationship between patient and physician, or pharmacist, or other professional False statements to patients, or PBM clients, in order to obtain business Secret payments to health plans to act against interest of their clients or members

FRAUD RISKS(2) Payments to PBM may set new best price or new Federal Supply Schedule ceiling price Potential Responsibility for off-label marketing of product by PBM(withdrawn FDA draft guidance?)

PBM/MANUFACTURER INTERACTION 1)rebates,discounts 2)administrative fees/formulary fees 3)payment for services(marketing, disease management, letters) 4)data purchases 5)detailing activities 6) unrestricted grants

Roles of Pharmacy Benefit Manager 1) ADMINISTRATOR OF RETAIL PHARMACY NETWORK 2) MAIL ORDER PHARMACY 3) PLAN DESIGNER/BENEFITS ADMINISTRATOR 4) NEGOTIATOR/AGENT FOR DRUG DISCOUNTS FROM MANUFACTURERS

Administering Retail Pharmacy Network Qualifying pharmacies for network participation Auditing, investigating pharmacies Negotiating price/service w/pharmacies Excluding pharmacies

Auditing,Investigating Pharmacies What are incentives? PBM is paid for each prescription processed, even fraudulent ones PBM is not paid for investigative services,law enforcement referrals PBM which finds fraud may be liable to clients for losses resulting from fraud, and to manufacturer for lower rebate payment Unlicensed/unauthorized physicians Shorting prescriptions No pickup-return to stock

Data Warehouse/Fraud Detector Largest non-governmental computer system Single biggest point of interaction between health plans and consumers-more transactions,more information No connection between med/surg information and drug information-is this a treating physician?is this drug for a diagnosis for which patient is being treated?

Mail Order Pharmacy Duties

PBMs operate mail order pharmacies PBMs operate mail order call centers,where patients and physicians call pharmacists for information PBMs provide pharmacy counseling These pharmacy activities are governed by OBRA 90 requirements and State Pharmacy Licensing Laws

Mail Order Pharmacy Duties Licensed Pharmacist must review prescription container and contents prior to dispensing(back end checking) to determine: Right drug Right strength Right patient Right patient instructions

Mail Order Pharmacy Duties Must not delegate pharmacist duties to non-pharmacists, except as specifically authorized by state law. Pharmacy techs Supervision requirements

Mail Order Pharmacy Duties Must dispense the prescription written by the physician unless: Physician authorizes change Drug is not in stock Pharmacist advises patient and physician that prescription will not be filled

Mail Order Pharmacy Duties Must provide number of pills ordered and paid for(no shorting) Must ship product ordered(or, in some states, generic equivalent) Must not put returned goods back in stock Must provide accurate response to WHIZMO (Where s my order) calls

Why would Mail Order Pharmacy Cheat? Pharmacist staffing shortages Pharmacist services are expensiveneed to reduce pharmacist labor Pharmacy contracts require prompt turnaround time-calls delay turnaround

How to Detect Mail Order Pharmacy Fraud Very Difficult-Data is in hands of perpetratorintentionally difficult to compile and analyze Employee complaints-to whom? Customer complaints-but whom do they complain to? What records of complaints? Pharmacy board, PBM, Employer, Health Plan

EMPLOYER OF LICENSED PHARMACISTS AND PHARMACY TECHNICIANS As an employer of licensed professionals, a PBM has a legal duty not to interfere with the performance of a pharmacist s professional duties.

PBM AS NEGOTIATOR/AGENT PBM negotiates price discounts, disease management programs, and rebates in return for formulary position with drug manufacturers on behalf of plans PBM has duty to act on behalf of principal 18 U.S.C. 1346 PBM has duty not to solicit or accept improper payments from manufacturers to affect their judgment or advice to clients

PBM AS NEGOTIATOR/ AGENT Most PBMs take payments from pharmaceutical companies to influence the ordering of prescription drugs by doctors, and the purchase of prescription drugs by patients. Potential problems with these payments:

If they don t disclose to physicians their financial interest in advocating a switch from one drug to another for a patient. calling on behalf of your health plan preferred formulary to keep benefit affordable

If they advocate switches which result in actual physical or emotional harm or risk of harm to patients.

If they advocate switches which result in higher costs to patient or the plan, and don t disclose this fact to both the patient and the plan.

If they advocate switches which result in other additional costs to patients and plans - physician visits, lab costs, in-patient hospitalization, and they don t disclose these facts to both the patient and the plan.

If they make secret deals with manufacturers to not disfavor that company s drugs, involving payments or stock arrangements, with no disclosure to patients, physicians, or payors.

C. GOOD BUSINESS, BEST PRICE VIOLATION, OR KICKBACK? PAYMENTS TO PBMs XYZ Drug Manufacturer offers PBM a rebate of $1 per script for each GERD prescription written by plan physicians and filled by pharmacists. PBM formulary manager counters with a demand for a $2 rebate per prescription.

XYZ states that they cannot pay $2 per prescription, because it will create a new Medicaid Best Price. However, they are prepared to offer value-added services which will equal a $2 rebate per prescription, with $1 going directly to PBM.

MEDICAID BEST PRICE MEDICAID DRUG REBATE PROGRAM 42 U.S.C. 1396r-8 Title XIX of the Social Security Act ( The Act ) The Omnibus Reconciliation Act of 1990, Section 401, - amended Section 1927 of the Act setting forth the requirements.

What is included in the Best Price Calculation? Anything that is paid or given to a customer or a payor as part of pricing transaction. 1. Rebates 2. Administrative fees 3. Access fees

WHAT FORM MIGHT PAYMENTS IN LIEU OF PRICE REDUCTIONS TAKE 1. Newsletters to physicians 2. Disease management programs 3. Patient review programs 4. Closed category fee 5. Formulary fee

4. Clinical pharmacists fees 5. Free or nominally priced products 6. Payments to play, service payments 7. Program grants 8. Up front fee, or licensing fee 9. Closed category fee 10.Sale of data

WHO IS LIABLE FOR BEST PRICE FALSE STATEMENT? 1. Manufacturer 2. Any person who conspires with or aids and abets manufacturer in making false statement about best price

18 U.S.C. Section 1035(a)(2) (False statements Health Care Matters) (a) Whoever, in any matter involving a health care benefit program, knowingly and willfully...

(1) Makes any materially false, fictitious, or fraudulent statements or representations, or makes or uses any materially false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection with the delivery of or payment for health care benefits, items, or services, shall be fined under this title or imprisoned not more than 5 years, or both.

PENDING CASES USA ex rel. Hunt v. Medco Health Solutions et al US complaint filed 9/29/03 Copy available on USAO website-

MEDCO HEALTH Prior enforcement actions 1995 State Attorneys General settlement issue: failure to disclose Merck ownership of Medco in advocating drug switches.

MEDCO HEALTH ACTIONS 1998 FTC Consent Decree FTC Claim Medco favored Merck drugs Consent decree Medco must accept all rebates, cannot share competitor price information, and must offer an open formulary

ADVANCE PCS Subpoenas served November, 1999 CIDs issued April, 2002 Pending CID enforcement actions and defense challenge to CIDs stayed

FEDERAL ENFORCEMENT ISSUES 1. False Claims Act (31 U.S.C. Sec. 3729-3733 2. Public Contracts Anti-Kickback Act (41 U.s.C. 52) 3. Intentional misrepresentation

4. Common law theories of law 5. Negligent misrepresentation 6. Payment under mistake of fact 7. Equitable claims of unjust enrichment 8. Mail Fraud/Health Care Fraud Injunction Act (18 U.S.C. 1345) 9. Restitution

State Enforcement Issues 1. Unfair Trade Practices 2. Pharmacy Board Regulations 3. Commercial Bribery/Kickback Statutes 4. State Insurance Regulation 5. False Claims Act (some states)

CONCLUSION WHAT ARE YOU PAYING TO PBMs WHAT DO YOU EXPECT TO GET FROM PBMs WHAT DISCLOSURE IS MADE BY PBMs OF FACT OF PAYMENT WHAT TECHNIQUES DO PBMs USE TO OBTAIN RESULTS YOU WANT IS TRANSACTION TRANSPARENT TO PHYSICIANS AND PATIENTS